Dual probe difference specimen imaging for prostate cancer margin assessment
暂无分享,去创建一个
Connor W. Barth | Broderick J. House | Summer L. Gibbs | S. Davis | Allison Solanki | Jocelyn A. Jones | Marcus J. Kwon
[1] H. Leung,et al. Raman Spectroscopy in Prostate Cancer: Techniques, Applications and Advancements , 2022, Cancers.
[2] A. Jemal,et al. Cancer statistics, 2022 , 2022, CA: a cancer journal for clinicians.
[3] Connor W. Barth,et al. Clinically relevant dual probe difference specimen imaging (DDSI) protocol for freshly resected breast cancer specimen staining , 2021, BMC cancer.
[4] Connor W. Barth,et al. Topical dual-probe staining using quantum dot-labeled antibodies for identifying tumor biomarkers in fresh specimens , 2020, PloS one.
[5] Connor W. Barth,et al. Fluorescence image-guided surgery: a perspective on contrast agent development , 2020, BiOS.
[6] Sunil Singhal,et al. Review of clinical trials in intraoperative molecular imaging during cancer surgery , 2019, Journal of biomedical optics.
[7] Ahmedin Jemal,et al. Cancer treatment and survivorship statistics, 2019 , 2019, CA: a cancer journal for clinicians.
[8] Pieterjan Debie,et al. Latest developments in molecular tracers for fluorescence image-guided cancer surgery. , 2019, The Lancet. Oncology.
[9] P. Carroll,et al. Assessment of 68Ga-PSMA-11 PET Accuracy in Localizing Recurrent Prostate Cancer: A Prospective Single-Arm Clinical Trial. , 2019, JAMA oncology.
[10] Scott C Davis,et al. Diagnostic performance of receptor-specific surgical specimen staining correlates with receptor expression level , 2019, Journal of biomedical optics.
[11] D. Byrd,et al. Real-time Visualization of Breast Carcinoma in Pathology Specimens From Patients Receiving Fluorescent Tumor-Marking Agent Tozuleristide. , 2018, Archives of pathology & laboratory medicine.
[12] Sunil Singhal,et al. Evaluation of Novel Tumor-Targeted Near-Infrared Probe for Fluorescence-Guided Surgery of Cancer. , 2018, Journal of medicinal chemistry.
[13] Sally M Hull,et al. Optimizing Glioma Detection Using an EGFR‐Targeted Fluorescent Affibody , 2018, Photochemistry and photobiology.
[14] Thomas D. Wang,et al. Targeted Optical Imaging Agents in Cancer: Focus on Clinical Applications , 2018, Contrast media & molecular imaging.
[15] Alexander L. Vahrmeijer,et al. Image-Guided Surgery in Patients with Pancreatic Cancer: First Results of a Clinical Trial Using SGM-101, a Novel Carcinoembryonic Antigen-Targeting, Near-Infrared Fluorescent Agent , 2018, Annals of Surgical Oncology.
[16] Guolan Lu,et al. Determination of Tumor Margins with Surgical Specimen Mapping Using Near-Infrared Fluorescence. , 2018, Cancer research.
[17] Travis L. Rice-Stitt,et al. Real-time, intraoperative detection of residual breast cancer in lumpectomy cavity walls using a novel cathepsin-activated fluorescent imaging system , 2018, Breast Cancer Research and Treatment.
[18] Johan F. Langenhuijsen,et al. Tumor-targeted Dual-modality Imaging to Improve Intraoperative Visualization of Clear Cell Renal Cell Carcinoma: A First in Man Study , 2018, Theranostics.
[19] B. Pogue,et al. Application of Fluorescence-Guided Surgery to Subsurface Cancers Requiring Wide Local Excision , 2018, Cancer control : journal of the Moffitt Cancer Center.
[20] J. Benson,et al. Novel techniques for intraoperative assessment of margin involvement , 2018, Ecancermedicalscience.
[21] Zachary T. Harmany,et al. Microscopy with ultraviolet surface excitation for rapid slide-free histology , 2017, Nature Biomedical Engineering.
[22] Scott C. Davis,et al. Optimizing fresh specimen staining for rapid identification of tumor biomarkers during surgery , 2017, Theranostics.
[23] Keith Paulsen,et al. Toxicity and Pharmacokinetic Profile for Single-Dose Injection of ABY-029: a Fluorescent Anti-EGFR Synthetic Affibody Molecule for Human Use , 2017, Molecular Imaging and Biology.
[24] A. Harootunian,et al. Intraoperative Tumor Detection Using a Ratiometric Activatable Fluorescent Peptide: A First-in-Human Phase 1 Study , 2017, Annals of Surgical Oncology.
[25] Alexander L Vahrmeijer,et al. SGM-101: An innovative near-infrared dye-antibody conjugate that targets CEA for fluorescence-guided surgery. , 2017, Surgical oncology.
[26] W. Stummer,et al. Randomized, Prospective Double-Blinded Study Comparing 3 Different Doses of 5-Aminolevulinic Acid for Fluorescence-Guided Resections of Malignant Gliomas , 2017, Neurosurgery.
[27] Vasilis Ntziachristos,et al. Tumor-Specific Uptake of Fluorescent Bevacizumab–IRDye800CW Microdosing in Patients with Primary Breast Cancer: A Phase I Feasibility Study , 2016, Clinical Cancer Research.
[28] Jonathan T. C. Liu,et al. Multiplexed Molecular Imaging of Biomarker-Targeted SERS Nanoparticles on Fresh Tissue Specimens with Channel-Compressed Spectrometry , 2016, PloS one.
[29] J. Olson,et al. Fluorescence Identification of Head and Neck Squamous Cell Carcinoma and High-Risk Oral Dysplasia With BLZ-100, a Chlorotoxin-Indocyanine Green Conjugate. , 2016, JAMA otolaryngology-- head & neck surgery.
[30] Jonathan T. C. Liu,et al. Surgical Guidance via Multiplexed Molecular Imaging of Fresh Tissues Labeled With SERS-Coded Nanoparticles , 2016, IEEE Journal of Selected Topics in Quantum Electronics.
[31] P. Low,et al. Intraoperative Molecular Diagnostic Imaging Can Identify Renal Cell Carcinoma. , 2016, The Journal of urology.
[32] Jonathan T. C. Liu,et al. Detection and delineation of oral cancer with a PARP1 targeted optical imaging agent , 2016, Scientific Reports.
[33] Milind Rajadhyaksha,et al. Quantitative molecular phenotyping with topically applied SERS nanoparticles for intraoperative guidance of breast cancer lumpectomy , 2016, Scientific Reports.
[34] Jeffrey K. Mito,et al. A mouse-human phase 1 co-clinical trial of a protease-activated fluorescent probe for imaging cancer , 2016, Science Translational Medicine.
[35] Connor W. Barth,et al. Polymeric Micelles as Carriers for Nerve-Highlighting Fluorescent Probe Delivery , 2015, Molecular pharmaceutics.
[36] T. Poeppel,et al. PSMA Ligands for Radionuclide Imaging and Therapy of Prostate Cancer: Clinical Status , 2015, Theranostics.
[37] Yu Winston Wang,et al. In vivo multiplexed molecular imaging of esophageal cancer via spectral endoscopy of topically applied SERS nanoparticles. , 2015, Biomedical optics express.
[38] Jinzuo Ye,et al. Intraoperative Imaging-Guided Cancer Surgery: From Current Fluorescence Molecular Imaging Methods to Future Multi-Modality Imaging Technology , 2014, Theranostics.
[39] W. Oyen,et al. Targeted Radionuclide and Fluorescence Dual-modality Imaging of Cancer: Preclinical Advances and Clinical Translation , 2014, Molecular Imaging and Biology.
[40] Scott C Davis,et al. Topical dual-stain difference imaging for rapid intra-operative tumor identification in fresh specimens. , 2013, Optics letters.
[41] Summer L. Gibbs,et al. Near infrared fluorescence for image-guided surgery. , 2012, Quantitative imaging in medicine and surgery.
[42] T. Church,et al. Long-term disease-specific functioning among prostate cancer survivors and noncancer controls in the prostate, lung, colorectal, and ovarian cancer screening trial. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[43] H. Ananias,et al. Expression of the gastrin‐releasing peptide receptor, the prostate stem cell antigen and the prostate‐specific membrane antigen in lymph node and bone metastases of prostate cancer , 2009, The Prostate.
[44] G. Sauter,et al. Photodynamic diagnosis using 5-aminolevulinic acid for the detection of positive surgical margins during radical prostatectomy in patients with carcinoma of the prostate: a multicentre, prospective, phase 2 trial of a diagnostic procedure. , 2009, European urology.
[45] Slave Trajanoski,et al. Heterogeneity of Prostate-Specific Membrane Antigen (PSMA) Expression in Prostate Carcinoma with Distant Metastasis , 2009, Pathology & Oncology Research.
[46] R. Knuechel,et al. Photodynamic diagnosis of prostate cancer using 5-aminolevulinic acid--first clinical experiences. , 2008, Urology.
[47] Zhenghong Lee,et al. Targeted treatment of prostate cancer , 2007, Journal of cellular biochemistry.
[48] Matthias D Hofer,et al. Prostate-specific membrane antigen expression as a predictor of prostate cancer progression. , 2007, Human pathology.
[49] M. Lein,et al. Photodynamic Therapy of Prostate Cancer by Means of 5-Aminolevulinic Acid-Induced Protoporphyrin IX – In vivo Experiments on the Dunning Rat Tumor Model , 2004, Urologia Internationalis.
[50] Prabhjot Kaur,et al. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.
[51] R. Zarbo,et al. Interinstitutional comparison of frozen section turnaround time. A College of American Pathologists Q-Probes study of 32868 frozen sections in 700 hospitals. , 1997, Archives of pathology & laboratory medicine.
[52] George L. Wright,et al. Detection and characterization of the prostate‐specific membrane antigen (PSMA) in tissue extracts and body fluids , 1995, International journal of cancer.
[53] A. Deblasio,et al. Sensitive nested reverse transcription polymerase chain reaction detection of circulating prostatic tumor cells: comparison of prostate-specific membrane antigen and prostate-specific antigen-based assays. , 1994, Cancer research.
[54] John Y. K. Lee,et al. Folate Receptor Near-Infrared Optical Imaging Provides Sensitive and Specific Intraoperative Visualization of Nonfunctional Pituitary Adenomas. , 2019, Operative neurosurgery.
[55] M. Sadelain,et al. A unique folate hydrolase, prostate-specific membrane antigen (PSMA): a target for immunotherapy? , 2001, Critical reviews in immunology.
[56] J. Lynch. Treatment of advanced prostate cancer. , 1993, The Journal of family practice.
[57] G. Murphy,et al. Monoclonal antibodies to a new antigenic marker in epithelial prostatic cells and serum of prostatic cancer patients. , 1987, Anticancer research.